The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐ FU in pancreatic cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hiroyuki Kato und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan. Hauptthemen laut MEDLINE: Fluorouracil, Dihydrouracil Dehydrogenase (NADP), Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite advances in the treatment of cancer, pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to the lack of effective therapies. Our previous study showed that Luteolin (Lut), a flavonoid, suppressed pancreatocarcinogenesis and reduced the expression of dihydropyrimidine dehydrogenase (DPYD), an enzyme that degrades pyrimidines such as 5‐fluorouracil (5‐FU), in PDACs. In this study, we investigated the role of DPYD and evaluated the therapeutic potential of combining 5‐FU with Lut in PDACs. Methods and Results PDAC cells overexpressing DPYD showed increased proliferation, and invasiveness, adding to the resistance to 5‐FU. The xenograft tumors of DPYD‐overexpressing PDAC cells also exhibit enhanced growth and invasion compared to the control xenograft tumors. RNA‐seq analysis of the DPYD‐overexpressing PDAC xenograft tumors revealed an upregulation of genes associated with metallopeptidase activity—MMP9 and MEP1A. Furthermore, the overexpression of MEP1A in PDAC was associated with invasion. Next, we investigated the combined effects of Lut, a DPYD suppressor, and 5‐FU on DPYD‐overexpressing xenograft tumors and PDAC of Pdx1‐Cre ; LSL‐KrasG12D/+ ; Trp53flox/flox(KPPC) mice. Neither single administration of 5‐FU nor Lut showed significant inhibitory effects; however, the combined administration of 5‐FU and Lut exhibited a significant tumor‐suppressive effect in both the xenograft tumors and KPPC models.
Conclusion
We have elucidated that DPYD expression contributes to proliferation, invasiveness, and 5‐FU resistance, in PDACs. The combination therapy of Lut and 5‐FU holds the potential for enhanced efficacy against PDACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan.
- Department of Anesthesiology, Nihon University School of Medicine, Tokyo, Japan.
- Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan.
- Department of Gastroenterology Surgery, Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, Japan.
- Department of Clinical Nutrition Center, Graduate School of Medicine, the University of Tokyo, Hongo, Tokyo, Japan.
ORCID-Profile: Hiroyuki Kato, Makoto Sano, Akihisa Kato
Zitieren
APA
Kato, H., Sato, M., Naiki-Ito, A., Inaguma, S., Sano, M., Komura, M., Nagayasu, Y., Xiaochen, K., Kato, A., Matsuo, Y., Ijichi, H., & Takahashi, S. (2024). The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐ FU in pancreatic cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70124
Vancouver
Kato H, Sato M, Naiki-Ito A, Inaguma S, Sano M, Komura M, et al. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐ FU in pancreatic cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70124
BibTeX
@article{Kato2024,
author = {Kato, Hiroyuki and Sato, Motonori and Naiki-Ito, Aya and Inaguma, Shingo and Sano, Makoto and Komura, Masayuki and Nagayasu, Yuko and Xiaochen, Kuang and Kato, Akihisa and Matsuo, Yoichi and Ijichi, Hideaki and Takahashi, Satoru},
title = {The role of DPYD and the effects of DPYD suppressor luteolin combined with 5‐ FU in pancreatic cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70124}
}
EUVIMED